#USA #AI Solutions #Wexford #Coeptis Pharmaceuticals #Technology Division

COEPTIS Secures $10 Million in Series A Financing

In a significant development for the biotechnology sector, COEPTIS, Inc. (Nasdaq: COEP), a leading innovator in technology-driven therapeutic solutions, has successfully completed a Series A Preferred financing round worth $10 million. This funding marks a pivotal step in the company's strategic plan to enhance its technological capabilities and integrate advanced artificial intelligence (AI) solutions into its operations.

A Growing Commitment to Innovation

As part of its ongoing efforts to stay at the forefront of biopharmaceutical innovation, COEPTIS announced an additional $5.7 million closure in its latest financing round, following an initial closure of $4.3 million. The announcement was met with enthusiastic support from investors, showcasing their strong confidence in the company's vision and capabilities. This financing initiative was spearheaded by CJC Investment Trust, whose board member, Christopher Calise, played a key role in the investment process.

Under the terms secured, the Series A Preferred shares can be converted into common stock at a price of $8.00 each, coupled with a significant 15% equity interest granted to investors in COEPTIS' newly established subsidiaries, SNAP Biosciences Inc. and GEAR Therapeutics Inc.

Unlocking New Opportunities for Growth

Brian Cogley, CFO of COEPTIS, expressed his excitement regarding the financing's role in bolstering the company's operational capabilities. "This funding is pivotal as we expand our operational capabilities and enhance shareholder value through our new Technology Division," he stated. This Technology Division is set to focus on the incorporation of cutting-edge AI-driven tools, enabling Coeptis to optimize its marketing strategies and enhance efficiencies within the highly regulated biopharmaceutical environment.

The financial proceeds designated for this phase will be utilized to strengthen the company's balance sheet, settle existing obligations, and support overall corporate strategies. Importantly, the funds will accelerate the integration of advanced AI systems designed to improve research and operational efficacy significantly.

Dave Mehalick, the current President and CEO of COEPTIS, reinforced the company's commitment to innovation, stating, "This additional financing enables COEPTIS to not just fortify its mission in cell therapy but also empowers us to drive innovation in technology and AI." These initiatives aim to establish a self-sustaining business model, crucial for long-term profitability and growth.

Integrated Approach to Therapies

COEPTIS remains focused on enhancing its portfolio of therapeutic solutions, targeting critical health challenges such as cancer, autoimmune disorders, and infectious diseases. By leveraging the recent acquisitions, including technology from NexGenAI Solutions Group, the company is exploring synergies between advanced AI capabilities and its developmental goals.

The therapeutic landscape that COEPTIS navigates is accentuated by partnerships with entities like Deverra Therapeutics, facilitating innovative treatment paths through licensed technologies, including a clinical-stage unmodified natural killer cell therapy. Further development of universal, multi-antigen CAR technology licensed from the University of Pittsburgh through SNAP-CAR remains a key area of focus.

COEPTIS’ commitment to regulatory compliance and patient care remains paramount, especially as it seeks to align all operations with the stringent guidelines delineated by the FDA. As the company forges ahead, the integration of technology and therapeutic development positions it strongly within the biopharmaceutical arena, emphasizing a future where patient outcomes and innovative solutions take center stage.

Conclusion

With the successful completion of its Series A financing round, COEPTIS is on a clear path towards enhancing patient care and fostering a culture of responsible innovation. Its approach not only emphasizes a robust operational framework but also illustrates a dedication to improving health outcomes through advanced technologies. This pivotal moment signals a promising future for COEPTIS as it strives to play a crucial role in the evolving biopharmaceutical landscape.